Gw Pharmaceuticals Plc Stock Net Income

GW Pharmaceuticals Plc fundamentals help investors to digest information that contributes to GW Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GWPH Stock. The fundamental analysis module provides a way to measure GW Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GW Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

GW Pharmaceuticals Plc Company Net Income Analysis

GW Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current GW Pharmaceuticals Net Income

    
  (58.13 M)  
Most of GW Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GW Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, GW Pharmaceuticals Plc reported net income of (58.13 Million). This is 117.03% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The net income for all United States stocks is 110.18% higher than that of the company.

GWPH Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GW Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GW Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GW Pharmaceuticals by comparing valuation metrics of similar companies.
GW Pharmaceuticals is currently under evaluation in net income category among related companies.

GWPH Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Other Consideration for investing in GWPH Stock

If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Stocks Directory
Find actively traded stocks across global markets